Who is sponsoring NCT05152498?

NCT05152498 is sponsored by Beijing Ditan Hospital.

What drugs are being tested in NCT05152498?

Interventions in NCT05152498: Fu Zheng Jie Du Hua Yu therapy.

What condition does NCT05152498 study?

NCT05152498 studies Hepatocellular Carcinoma.

Is NCT05152498 still recruiting?

NCT05152498 is currently status unknown. Last updated 9 December 2021.

Last reviewed 2021-12-09 · How we verify

NCT05152498

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)

Status unknown EARLY_PHASE1 Last updated 9 December 2021

What this trial tests

EARLY_PHASE1 trial testing Fu Zheng Jie Du Hua Yu therapy in Hepatocellular Carcinoma in 142 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Beijing Ditan Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	142
Start date	1 January 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Fu Zheng Jie Du Hua Yu therapy — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Beijing Ditan Hospital

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The treatment of HBV related hepatocellular carcinoma has always been a worldwide problem. The aim of this study is to alleviate the progression of hepatitis B related hepatocellular carcinoma by the Chinese medicine "Fu Zheng Jie Du Hua Yu" Principle.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.
Wu J, Tang G, Cheng CS, Yeerken R, et al · · 2024 · cited 34× · PMID 39354529 · DOI 10.1186/s12943-024-02136-2

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Beijing Ditan Hospital trials

Trials by the same sponsor.

NCT06642740 — Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia · enrolling by invitation
NCT06777173 — Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults · NA · enrolling by invitation
NCT05929963 — Observational Study of the Interaction Between Hepatitis C Virus Infection and Pregnancy · unknown
NCT05812612 — UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease · unknown
NCT05765279 — A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of I · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05152498 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Ditan Hospital
Last refreshed: 9 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05152498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing